Brenus Pharma, a pioneering company focused on developing therapeutic cancer vaccines through its innovative STC platform, has successfully graduated from the Creative Destruction Lab (CDL) Cancer program. This global mentorship initiative supports science-based companies that are accelerating cancer treatment innovations. Brenus was selected for the program a year ago, distinguishing itself during a scientific evaluation by Dr. John Bell, a prominent researcher at the Ottawa Hospital Cancer Research Institute and a professor at the University of Ottawa.
Brenus, along with nine other companies, completed the program’s rigorous four sessions held across North America from October 2023 to June 2024. The company sought strategic international guidance to advance its platform and lead candidate targeting colorectal cancer.
Throughout the program, Brenus presented its objectives and updates, which were critically assessed by the CDL community and mentors, including successful entrepreneurs, investors, corporate partners, and key opinion leaders from prestigious institutions such as the University of New York, Oxford, Toronto, and British Columbia. This support was crucial in validating Brenus Pharma’s roadmap and accelerating its progress in research and development, finance, and partnerships.
“The CDL sessions, based on an interesting ‘creative destruction’ method, allowed us to leverage expertise across the CDL community and anticipate the next key steps to bring our innovation to patients with urgent unmet needs,” said Paul Bravetti, CEO of Brenus Pharma. “This year has already been rich in achievements for Brenus, and we will continue to drive operational excellence to bring our company further. We are proud to have undertaken the CDL challenge and we thank our mentors for their trust.”
Brenus’s participation in the CDL Cancer program marks a significant milestone in its mission to develop next-generation cancer vaccines, setting the stage for continued advancements in the fight against cancer.